Global Chronic Plaque Psoriasis Market Report

Global Chronic Plaque Psoriasis Market is poised for a significant growth, with market size projected to surge from USD 1.26 Billion in 2024 to USD 2.44 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.56% during the forecast period.

Chronic Plaque Psoriasis Market Size and Forecast 2025 to 2033

The chronic plaque psoriasis market is experiencing robust growth driven by a confluence of factors, primarily the increasing global prevalence of the condition. Psoriasis, a chronic autoimmune disease, affects millions worldwide, with plaque psoriasis being the most common form. The rising awareness about psoriasis and advancements in diagnostic tools are contributing to a higher diagnosis rate. Furthermore, the significant unmet need for effective and long-lasting treatments propels research and development activities, leading to the introduction of novel therapeutic options.

Opportunities within this market are substantial, particularly in the development of biologics and small molecule drugs that offer superior efficacy and safety profiles compared to conventional therapies. The expanding healthcare infrastructure in emerging economies and improved access to treatment are also fostering market expansion. The shift towards personalized medicine approaches, leveraging genetic and molecular insights, presents a unique avenue for innovative drug development. Additionally, the growing focus on improving patient quality of life and adherence to treatment regimens is creating opportunities for advanced drug delivery systems and digital health solutions.

Market Dynamics

Chronic Plaque Psoriasis Market Drivers

• Rising Prevalence of Psoriasis Worldwide: The increasing incidence and prevalence of psoriasis globally serve as a primary driver for the chronic plaque psoriasis market. According to the National Psoriasis Foundation, psoriasis affects approximately 8 million Americans, with plaque psoriasis being the most common type, accounting for about 80% to 90% of all cases. This widespread prevalence translates into a large patient pool requiring ongoing medical management and advanced therapeutic interventions. The chronic and relapsing nature of the disease necessitates long-term treatment, contributing to sustained demand for medications. Moreover, factors such as genetic predisposition, environmental triggers, and lifestyle changes are believed to contribute to the rising burden of psoriasis, thereby bolstering market growth as more individuals seek diagnosis and treatment. Public health initiatives aimed at early detection and management also play a role in increasing the diagnosed patient population, as reported by the Centers for Disease Control and Prevention.
• Advancements in Biologic Therapies: The continuous innovation and introduction of highly effective biologic therapies represent a significant driver for the chronic plaque psoriasis market. Biologics, which target specific components of the immune system involved in psoriasis pathogenesis, have revolutionized treatment paradigms by offering superior efficacy and improved safety profiles compared to traditional systemic therapies. For instance, data from the National Institute of Arthritis and Musculoskeletal and Skin Diseases highlights the substantial improvements in Psoriasis Area and Severity Index (PASI) scores observed with biologic treatments, often achieving PASI 75 or even PASI 90 responses in a significant proportion of patients. This enhanced clinical outcome has led to increased adoption of biologics, despite their higher cost, as both physicians and patients prioritize effective disease control and quality of life. The ongoing research and development in this segment, as evidenced by clinical trial registries maintained by the National Institutes of Health, continue to bring forth novel biologics with diverse mechanisms of action, further expanding treatment options.
• Growing Awareness and Improved Diagnosis: Increased public awareness regarding psoriasis and its impact, coupled with advancements in diagnostic capabilities, are significant drivers for the chronic plaque psoriasis market. Educational campaigns by organizations such as the American Academy of Dermatology have contributed to reducing stigma and encouraging individuals to seek medical attention for skin conditions. This heightened awareness leads to earlier diagnosis, preventing disease progression and improving treatment outcomes. Furthermore, the availability of advanced diagnostic tools and techniques, including histopathological examination and dermatoscopy, allows for more accurate and timely identification of plaque psoriasis. The Centers for Disease Control and Prevention emphasize the importance of early and accurate diagnosis in managing chronic diseases effectively, which in turn drives the demand for appropriate pharmacological interventions. Improved understanding among primary care physicians regarding psoriasis symptoms also contributes to timely referrals to dermatologists, expanding the patient pool for specialized treatments.
• Rising Healthcare Expenditure and Access to Care: The increasing global healthcare expenditure, particularly in developed nations, and improved access to advanced medical care are pivotal drivers for the chronic plaque psoriasis market. Governments and private payers are increasingly allocating resources towards the management of chronic diseases, including psoriasis, recognizing the long-term impact on patient quality of life and productivity. According to the World Health Organization, global health spending continues to rise, enabling broader coverage for specialized treatments and medications. This enhanced financial accessibility allows more patients to afford and pursue advanced therapies like biologics, which might have been cost-prohibitive in the past. Furthermore, the expansion of healthcare infrastructure, particularly in developing regions, and the implementation of universal healthcare coverage in some countries are facilitating better access to dermatological specialists and prescription medications for chronic plaque psoriasis, thereby expanding the market reach and driving therapeutic demand.

Chronic Plaque Psoriasis Market Opportunities

• Emergence of Novel Oral Small Molecule Drugs: The development and approval of novel oral small molecule drugs present a significant opportunity in the chronic plaque psoriasis market. These therapies offer the convenience of oral administration, addressing patient preferences for non-injectable options, and providing an alternative for those hesitant about biologics. Research supported by the National Institutes of Health indicates a growing pipeline of oral agents that target specific intracellular signaling pathways implicated in psoriasis, offering a distinct mechanism of action from biologics. This development broadens the treatment landscape, potentially increasing patient adherence and providing more personalized therapeutic choices. The accessibility and ease of use of oral medications can lead to wider adoption, particularly in regions where access to specialized clinics for injectable therapies might be limited.
• Development of Biosimilars: The increasing development and introduction of biosimilars for existing biologic therapies represent a substantial opportunity for market expansion in chronic plaque psoriasis. Biosimilars offer a cost-effective alternative to their reference biologic products, potentially increasing patient access to highly effective treatments and reducing healthcare expenditures. The U.S. Food and Drug Administration's efforts to approve biosimilars aim to foster competition and lower drug costs, which can significantly expand the patient population able to afford these advanced therapies. This affordability can drive uptake in both established and emerging markets, leading to a greater overall market penetration for biologic-like treatments. The availability of biosimilars can alleviate budget constraints for healthcare systems and patients, thereby improving treatment access for a larger segment of the psoriasis population.
• Focus on Personalized Medicine Approaches: The growing emphasis on personalized medicine, driven by advancements in genomics and biomarkers, offers a compelling opportunity in the chronic plaque psoriasis market. Tailoring treatment strategies based on individual patient characteristics, genetic profiles, and disease biomarkers can optimize therapeutic outcomes and minimize adverse effects. The National Human Genome Research Institute highlights the potential of genomic information to guide drug selection, allowing for more precise and effective interventions. This approach can lead to higher treatment success rates and improved patient satisfaction, ultimately driving demand for diagnostic tools and therapies that align with personalized medicine principles. The ability to predict treatment response or identify patients at risk of adverse events before initiating therapy represents a significant advancement that can enhance market value.
• Expansion into Emerging Markets: The burgeoning healthcare infrastructure and increasing disposable incomes in emerging economies present a significant market opportunity for chronic plaque psoriasis treatments. Countries in Asia-Pacific, Latin America, and the Middle East and Africa are witnessing a rise in chronic disease prevalence, including psoriasis, coupled with improving access to advanced medical care. According to the World Bank, many of these economies are experiencing rapid economic growth, leading to increased healthcare spending. This expansion offers untapped patient populations for pharmaceutical companies, as awareness and diagnostic capabilities improve in these regions. Strategic market entry and investment in patient education and physician training programs can unlock substantial growth potential, addressing previously unmet medical needs in these underserved areas.

Chronic Plaque Psoriasis Market Restrain & Challenges

• High Cost of Biologic Therapies: The elevated cost associated with biologic therapies presents a significant restraint and challenge in the chronic plaque psoriasis market. While highly effective, these advanced treatments can be prohibitively expensive, posing a substantial financial burden on patients, healthcare systems, and payers. According to data from the Centers for Medicare & Medicaid Services, the cost of specialty drugs, including biologics for autoimmune conditions, continues to rise, impacting overall healthcare expenditures. This high cost often leads to limited access, particularly in regions with less comprehensive insurance coverage or in countries with budget-constrained public health systems. The financial strain can result in patients delaying treatment, opting for less effective but cheaper alternatives, or even discontinuing therapy, thereby hindering optimal disease management and market growth. This challenge underscores the need for more affordable treatment options and innovative pricing models.
• Lack of Awareness and Misdiagnosis in Developing Regions: A significant restraint in the chronic plaque psoriasis market, especially in developing regions, is the lack of widespread awareness about the disease and its potential for misdiagnosis. In many parts of the world, psoriasis is often mistaken for other common skin conditions, leading to delayed or incorrect treatment. The World Health Organization has highlighted the global disparities in access to dermatological care and specialized diagnostic services. This unawareness among both the general public and, at times, healthcare professionals in primary care settings can result in patients not receiving appropriate and timely intervention for their chronic plaque psoriasis. The limited understanding of the chronic nature and systemic implications of psoriasis also contributes to a lower prioritization of treatment, thereby impeding market penetration for advanced therapies.
• Adverse Effects and Safety Concerns of Existing Therapies: Despite their efficacy, many existing therapies for chronic plaque psoriasis, including some biologics and conventional systemic drugs, are associated with potential adverse effects and safety concerns. For instance, some treatments may increase the risk of infections, cardiovascular events, or other serious side effects, as documented by the U.S. Food and Drug Administration in post-market surveillance data. These safety profiles necessitate careful patient selection, monitoring, and can lead to patient reluctance or non-adherence to prescribed regimens. Physicians must weigh the benefits against the risks, which can limit the broader adoption of certain therapies, especially in patients with co-morbidities. The ongoing need for long-term safety data and the potential for new or rare adverse events to emerge post-approval remain a continuous challenge for manufacturers and prescribers, impacting market growth.
• Patient Non-Adherence to Treatment Regimens: Patient non-adherence to prescribed treatment regimens poses a considerable restraint and challenge in the chronic plaque psoriasis market. The long-term nature of psoriasis treatment, coupled with the need for consistent medication intake, can lead to patients discontinuing therapy due to various factors such as side effects, perceived lack of efficacy, inconvenience of administration, or financial burdens. A study published by the National Institutes of Health indicated that adherence rates for chronic conditions like psoriasis often fall below optimal levels, impacting treatment outcomes. This non-adherence can result in disease flares, reduced quality of life, and increased healthcare utilization, ultimately affecting the overall effectiveness of available therapies and the potential revenue for pharmaceutical companies. Addressing this challenge requires comprehensive patient education, supportive care, and the development of more patient-friendly drug formulations and administration methods.

Current Trends in the Chronic Plaque Psoriasis Market

• Shift Towards Biologic and Biosimilar Utilization: A prominent trend in the chronic plaque psoriasis market is the increasing shift towards the utilization of biologic and biosimilar therapies. These advanced treatments, which target specific inflammatory pathways, have demonstrated superior efficacy and sustained remission rates compared to traditional systemic therapies. According to the National Psoriasis Foundation, biologics are often recommended for moderate to severe psoriasis due to their effectiveness in clearing skin lesions and improving quality of life. The growing availability of biosimilars, which offer similar efficacy and safety profiles to their reference biologics at a potentially lower cost, is further accelerating this trend. This move not only expands access to these highly effective treatments for a broader patient population but also fosters competition within the market, as indicated by the increasing number of biosimilar approvals by the U.S. Food and Drug Administration.
• Emergence of Oral Small Molecule Inhibitors: The chronic plaque psoriasis market is witnessing a significant trend with the emergence and increasing adoption of oral small molecule inhibitors. These therapies, unlike injectable biologics, offer the convenience of oral administration, which can improve patient adherence and preference. Research highlighted by the National Institute of Arthritis and Musculoskeletal and Skin Diseases points to the development of novel oral agents that target specific molecular pathways involved in psoriasis pathogenesis, such as JAK inhibitors and PDE4 inhibitors. These drugs provide an important alternative for patients who may not be candidates for or prefer not to use injectable biologics. The pipeline for such oral therapies remains robust, indicating a sustained interest in developing convenient yet effective treatment options, thereby expanding the therapeutic landscape and providing more choices for patients and clinicians.
• Increased Focus on Personalized Medicine and Biomarkers: A growing trend in the chronic plaque psoriasis market is the intensified focus on personalized medicine approaches, leveraging advancements in biomarkers and genetic understanding. This trend aims to tailor treatment strategies to individual patient profiles, optimizing efficacy and minimizing adverse events. Organizations like the National Institutes of Health are supporting research into identifying genetic markers and other biomarkers that can predict response to specific therapies or identify patients at higher risk of developing certain side effects. This move towards precision medicine enables clinicians to make more informed treatment decisions, leading to better patient outcomes and more efficient resource utilization. The integration of diagnostic tests that identify relevant biomarkers with therapeutic interventions is becoming increasingly important, shaping the future of psoriasis management.
• Integration of Digital Health Solutions and Tele-dermatology: The chronic plaque psoriasis market is experiencing a notable trend towards the integration of digital health solutions and the expansion of tele-dermatology services. These technologies are enhancing patient monitoring, improving treatment adherence, and facilitating remote consultations. For instance, mobile application designed for psoriasis patients can help track symptoms, medication usage, and treatment progress, providing valuable data for both patients and healthcare providers. The Centers for Disease Control and Prevention recognize the role of telehealth in expanding access to care, particularly for chronic conditions. Tele-dermatology allows patients in remote areas or those with limited mobility to receive expert dermatological advice without the need for in-person visits, improving accessibility to specialists and ongoing management of their condition, thereby streamlining care delivery and patient engagement.

Segmentation Insights

Chronic Plaque Psoriasis market Analysis, By Drug Class

By drug class, the market is divided into biologics and small molecule drugs .

• The largest and fastest segment in the chronic plaque psoriasis market by drug class is biologics. This dominance can be attributed to their exceptional efficacy in achieving significant skin clearance and improving the quality of life for patients with moderate to severe chronic plaque psoriasis. Biologics specifically target key inflammatory pathways implicated in psoriasis pathogenesis, leading to superior clinical outcomes compared to traditional systemic therapies. Their ability to induce and maintain long-term remission, often with a favorable safety profile compared to older systemic drugs, has led to widespread adoption by dermatologists globally. The consistent introduction of novel biologics with improved mechanisms of action and better safety profiles further solidifies their leading position, as healthcare providers and patients prioritize effective disease control. The continuous innovation within the biologic space, leading to the approval of new molecules with enhanced efficacy and safety, contributes significantly to their accelerated adoption. Furthermore, the increasing patient and physician awareness regarding the benefits of biologics for moderate to severe disease is driving their prescription rates. The expansion of healthcare coverage in various regions and the rising disposable incomes also enable more patients to access these high-cost yet highly effective treatments. The pipeline for biologic drugs remains robust, with many promising candidates in late-stage clinical development, ensuring sustained growth in this segment as they become available to the market.

Chronic Plaque Psoriasis market Analysis, By Route Of Administration

By Route Of Administration, the market is categorized into Injectable, Oral, Topical.

• The largest segment in the chronic plaque psoriasis market by route of administration is injectable. This dominance is primarily due to the high efficacy and rapid onset of action offered by injectable biologic therapies. Biologics, which are typically administered via subcutaneous injection or intravenous infusion, are the cornerstone of treatment for moderate to severe chronic plaque psoriasis, delivering systemic effects that significantly improve skin clearance and reduce disease burden. The consistent and predictable systemic exposure achieved through injections allows for better control of the underlying inflammatory processes. Furthermore, many patients find the convenience of infrequent injections, often self-administered, to be preferable over daily oral medications or extensive topical applications, contributing to the segment's leading position.
• The fastest-growing segment within the chronic plaque psoriasis market by route of administration is oral. This rapid growth is driven by the increasing availability and adoption of novel oral small molecule drugs. These therapies offer the significant advantage of oral administration, which is highly preferred by a substantial portion of the patient population due to its convenience and ease of use, eliminating the need for injections. The development of oral agents that specifically target inflammatory pathways involved in psoriasis has provided an effective alternative for patients who may not be candidates for or prefer not to use injectable treatments. The robust pipeline of new oral therapies with promising efficacy and safety profiles further fuels this growth, as more patient-friendly and accessible options become available in the market.

Chronic Plaque Psoriasis market Analysis, By Distribution Channel

By Distribution Channel, the market is categorized into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

• The largest segment in the chronic plaque psoriasis market by distribution channel is retail pharmacy. This dominance is attributed to the widespread accessibility and convenience offered by retail pharmacies, which serve as the primary point of access for prescription medications for the majority of patients with chronic plaque psoriasis. Patients can easily pick up their oral medications and topical treatments from their local retail pharmacies, making it a convenient option for ongoing disease management. Furthermore, many retail pharmacies also offer specialized services for biologic medications, including patient counseling and sometimes even administering initial doses, thus solidifying their leading position in the distribution landscape.
• The fastest-growing segment within the chronic plaque psoriasis market by distribution channel is online pharmacy. This rapid growth is driven by the increasing digitalization of healthcare and the convenience and discretion offered by online platforms. Online pharmacies provide patients with the ability to order their medications from the comfort of their homes, often with competitive pricing and discreet delivery. This channel is particularly appealing for chronic conditions like psoriasis, where patients require regular refills and may prefer not to visit physical pharmacies frequently. The COVID-initiated surge in telehealth and online services has further accelerated the adoption of online pharmacies, making them a rapidly expanding and increasingly important distribution channel for chronic plaque psoriasis treatments.

Chronic Plaque Psoriasis Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the chronic plaque psoriasis market is North America. This region's dominance is primarily attributed to several key factors, including a high prevalence of psoriasis, well-established healthcare infrastructure, and significant healthcare expenditure. The presence of major pharmaceutical companies and robust research and development activities also contribute to the early adoption of novel and advanced therapies, particularly biologics, in this region. Furthermore, strong reimbursement policies and a high level of awareness among both patients and healthcare professionals regarding psoriasis diagnosis and treatment further solidify North America's leading position in terms of market share and therapeutic uptake.
• The fastest-growing region in the chronic plaque psoriasis market is Asia-Pacific. This rapid growth is driven by improving healthcare infrastructure, increasing disposable incomes, and a rising awareness about psoriasis in countries like China, India, and Japan. The large and growing patient population in these countries, coupled with expanding access to advanced medical treatments, is fueling market expansion. Furthermore, a supportive regulatory environment and increasing investment by global pharmaceutical companies in these emerging markets are contributing to the accelerated adoption of innovative therapies for chronic plaque psoriasis across the Asia-Pacific region.

Chronic Plaque Psoriasis Market Competitive Overview

The competitive landscape of the chronic plaque psoriasis market is characterized by the presence of several prominent pharmaceutical companies vying for market share through product innovation, strategic collaborations, and geographical expansion. These companies are actively engaged in research and development to introduce novel therapeutic agents, particularly biologics and small molecule drugs, with improved efficacy, safety profiles, and patient convenience. The market exhibits intense competition, driven by the need to address the significant unmet medical needs of patients suffering from chronic plaque psoriasis. Companies are also focusing on biosimilar development to offer more affordable alternatives to existing high-cost biologics, thereby increasing market access and penetration. Strategic alliances and partnerships are common, aimed at leveraging expertise and expanding product portfolios. The emphasis remains on developing treatments that offer sustained disease remission and enhance the overall quality of life for patients.

Leading Market Players in the Chronic Plaque Psoriasis Market

• AbbVie Inc.: AbbVie is a global biopharmaceutical company with a strong presence in the immunology market, including chronic plaque psoriasis. The company has a significant portfolio of treatments, primarily focusing on biologics that have established themselves as foundational therapies for various autoimmune conditions. Their commitment to research and development in immunology has led to the introduction of innovative solutions that address the complex inflammatory pathways involved in psoriasis. AbbVie continues to invest in clinical trials to expand the indications for their existing products and to bring forth new therapeutic options, demonstrating a sustained focus on improving patient outcomes in chronic plaque psoriasis. Their extensive commercial footprint and patient support programs further bolster their position in the market.
• Johnson & Johnson: Johnson & Johnson is a diversified healthcare company with a notable presence in the chronic plaque psoriasis market through its pharmaceutical segment. The company offers a range of biologics that have been instrumental in transforming the treatment landscape for moderate to severe plaque psoriasis. Their strategic approach involves continuous innovation and the development of therapies that provide effective and long-lasting disease control for patients. Johnson & Johnson is committed to advancing scientific understanding of autoimmune diseases and translating that knowledge into meaningful therapeutic solutions. The company also focuses on patient access and education initiatives, aiming to ensure that individuals with chronic plaque psoriasis receive appropriate and timely care.
• Novartis AG: Novartis AG is a leading global pharmaceutical company with a significant contribution to the chronic plaque psoriasis market. The company has a strong portfolio of treatments, including biologics, that target specific inflammatory cytokines involved in psoriasis pathogenesis. Novartis is dedicated to pioneering innovative therapies that offer superior efficacy and safety profiles, addressing the high unmet needs of patients with chronic plaque psoriasis. Their investment in cutting-edge research and development aims to bring forth next-generation treatments that provide sustained disease remission and improve patient quality of life. Novartis also emphasizes global access to their medicines through various initiatives and partnerships, demonstrating a commitment to serving a broad patient population.

Top Strategies Followed by Players

• Strategic Acquisitions and Collaborations: A prominent strategy followed by players in the chronic plaque psoriasis market is engaging in strategic acquisitions and collaborations. Companies are actively seeking to expand their product pipelines, gain access to innovative technologies, and strengthen their market presence by acquiring smaller biotech firms with promising drug candidates or partnering with academic institutions and research organizations. This approach allows established pharmaceutical companies to leverage external expertise and accelerate the development and commercialization of novel therapies. For instance, data from industry reports frequently highlight instances of major players acquiring rights to late-stage assets or forming joint ventures to co-develop new treatments, thereby enhancing their competitive edge and broadening their therapeutic offerings in the chronic plaque psoriasis space.
• Intensified Research and Development (R&D) for Novel Therapies: Leading market players are heavily investing in intensified research and development (R&D) for novel therapies to address the evolving needs of chronic plaque psoriasis patients. This strategy focuses on discovering and developing new mechanisms of action, particularly in the realm of targeted therapies beyond existing biologics. Companies are exploring small molecules, gene therapies, and even cell-based therapies that could offer improved efficacy, safety, or convenience. The commitment to R&D is evidenced by the substantial number of ongoing clinical trials for chronic plaque psoriasis across various phases, as reported by clinical trial databases maintained by government agencies. This continuous innovation aims to bring forth breakthrough treatments that can provide longer-lasting remission and cater to a wider range of patient profiles, including those who do not respond to current treatments.
• Expansion into Emerging Markets and Patient Access Initiatives: Another key strategy employed by players in the chronic plaque psoriasis market involves expanding their presence into emerging markets and implementing patient access initiatives. Recognizing the growing patient populations and improving healthcare infrastructure in regions such as Asia-Pacific and Latin America, pharmaceutical companies are strategically focusing on increasing the availability of their chronic plaque psoriasis treatments in these areas. This includes securing regulatory approvals, establishing local distribution networks, and engaging in educational programs for healthcare professionals and patients. Moreover, companies are also implementing patient assistance programs and working with healthcare payers to improve affordability and access to high-cost therapies, as evidenced by reports from various health organizations promoting equitable access to essential medicines globally. This dual approach aims to tap into underserved markets while ensuring that more patients can benefit from effective treatments.

List of Companies Profiled in the Report are:

• Pfizer Inc
• Johnson & Johnson
• Merck & Co. Inc.
• AbbVie Inc
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Amgen Inc
• Boehringer Ingelheim International GmbH
• Biogen Inc
• UCB S.A.
• Dr. Reddy’s Laboratories Ltd
• Innovent Biologics Inc
• Dong-A ST Co. Ltd
• Alumis GmbH Co. KG

Global Chronic Plaque Psoriasis Market Report: Scope

List of Segments Covered

This section of the Chronic Plaque Psoriasis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Biologics
• Small Molecule Drugs

By Route Of Administration

• Injectable
• Oral
• Topical

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy